Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8743-8747

  Ehsani, Laleh ^a   Osunkoya, Adeboye O ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Microsatellite instability; Renal pelvis; Urothelial carcinoma

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CANCER; MALE; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; RENAL PELVIS UROTHELIAL CARCINOMA; TRANSITIONAL CELL CARCINOMA; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; GENETICS; KIDNEY PELVIS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MICROSATELLITE INSTABILITY; MUTS HOMOLOG 2 PROTEIN; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS;

EID: 84919838029     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2141-4     Document Type: Article

References (35)

1. Oldbring J, Glifberg I, Mikulowski P, et al. Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. J Urol. 1989;141:1311–3.
2. Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601.
3. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61:3230–9.
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–9.
5. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.
6. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010;47(7):464–70.
7. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430e3.
8. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001;19:4074e80.
9. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105e10.
10. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17e25.
11. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005;42:491e6.
12. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol. 1998;160:466e70.
13. Lynch HT, Taylor RJ, Lynch JF, et al. Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. Am J Gastroenterol. 2003;98:664e70.
14. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020e7.
15. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677e85.
16. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102:193e201.
17. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48–55.
18. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.
19. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamysin resistance are associated with MutLA and mismatch repair deficiency in an ovarian tumour cell line. J Biol Chem. 1996;271:19645–8.
20. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816–9.
21. Arzimanoglou II, Gilbert F, Barber HR. Microsatellite instability in human solid tumors. Cancer. 1998;82:1808–20.
22. Staebler A, Lax SF, Ellenson LH. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol. 2000;31:354–8.
23. Cunningham JM, Cunningham JM, Christensen ER, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58(15):3455–60.
24. Blaszyk H, Wang L, Dietmaier W, et al. Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis. Mod Pathol. 2002;15:790–7.
25. Hartmann A, Dietmaier W. Hofstädter F, et al Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability. Hum Pathol. 2003;34(3):222–7.
26. Chiura AN, Wirtschafter A, Bagley DH. Upper urinary tract inverted papillomas. Urology. 1998;52:514–6.
27. Rey A, Lara PC, Redondo E, et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter: relation to tumor proliferation and survival. Cancer. 1997;79:2178–85.
28. Bilim VN, Tomita Y, Kawasaki T, et al. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium. Cancer Lett. 1998;128:87–92.
29. Hartmann A, Zanardo L, Bocker-Edmonston T, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 2002;62(23):6796–802.
30. Rouprêt M, Fromont G, Azzouzi AR, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65(6):1233–7.
31. Rouprêt M, Azzouzi AR, Cussenot O. Microsatellite instability and transitional cell Carcinoma of the upper urinary tract. BJU Int. 2005;96(4):489–92.
32. Ruszkiewicz A, Bennett G, Moore J, et al. Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathol- ogy. 2002;34:541–7.
33. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043–8.
34. Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut. 2004;53:371–5.
35. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.